Form 13-F position report

ORAMED PHARMACEUTICALS INC

Reported by Squarepoint Ops LLC

ORMP CUSIP 68403P203 Manager CIK 0001642575

First reported at 20,353 shares this quarter.

New
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 20,353 Quarter-end amount reported
Reported value $95,049 Fair value at quarter end
Consecutive quarters held 1 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 563000
2022-03-31 0
2022-06-30 532000
2022-09-30 0
2023-06-30 122311
2023-09-30 137923
2023-12-31 270908
2024-03-31 260245
2024-06-30 210118
2024-09-30 203386
2024-12-31 131742
2025-03-31 101691
2025-06-30 103658
2025-09-30 78846
2025-12-31 166075
2026-03-31 0
2026-09-30 95049

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for ORAMED PHARMACEUTICALS INC held by Squarepoint Ops LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 20,353 +20,353 (0.0%) < 0.01% $95,049 2026-11-09
Q1 2026 Reduced 0 -58,272 (-100.0%) 0 $0 2026-05-15
Q4 2025 Added 58,272 +28,406 (95.1%) < 0.01% $166,075 2026-02-13
Q3 2025 Reduced 29,866 -16,204 (-35.2%) < 0.01% $78,846 2025-11-14
Q2 2025 Reduced 46,070 -1,449 (-3.0%) < 0.01% $103,658 2025-08-14
Q1 2025 Reduced 47,519 -6,920 (-12.7%) < 0.01% $101,691 2025-05-15
Q4 2024 Reduced 54,439 -28,916 (-34.7%) < 0.01% $131,742 2025-02-14
Q3 2024 Added 83,355 +1,597 (2.0%) < 0.01% $203,386 2024-11-14
Q2 2024 Reduced 81,758 -7,367 (-8.3%) < 0.01% $210,118 2024-08-14
Q1 2024 Reduced 89,125 -28,151 (-24.0%) < 0.01% $260,245 2024-05-15
Q4 2023 Added 117,276 +64,432 (121.9%) < 0.01% $270,908 2024-02-14
Q3 2023 Added 52,844 +18,679 (54.7%) < 0.01% $137,923 2023-11-14
Q2 2023 New 34,165 +34,165 (0.0%) < 0.01% $122,311 2023-08-14
Q3 2022 Reduced 0 -116,065 (-100.0%) 0 $0 2022-11-14
Q2 2022 New 116,065 +116,065 (0.0%) < 0.01% $532,000 2022-08-15
Q1 2022 Reduced 0 -39,433 (-100.0%) 0 $0 2022-05-16
Q4 2021 New 39,433 +39,433 (0.0%) < 0.01% $563,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

104 managers reported ORAMED PHARMACEUTICALS INC for Q3 2026.

Managers reporting ORAMED PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
MERCER GLOBAL ADVISORS INC ADV Added 3,812,682 +2,142 0.02% $17,805,225 3 qtrs
Aquamarine Financial Cayman Ltd Added 2,653,567 +141,392 0.64% $12,392,158 5 qtrs
Murchinson Ltd Added 2,142,118 +851,824 1.1% $10,003,691 12 qtrs
Gem Investment Advisors LLC Unchanged 1,998,802 0 6.49% $9,334,405 4 qtrs
BlackRock Inc Added 1,840,347 +232,236 < 0.01% $8,594,420 9 qtrs
BML Capital Management LLC Added 884,392 +18,123 2.2% $4,130,111 15 qtrs
BOOTHBAY FUND MANAGEMENT LLC Added 820,574 +241,936 0.06% $3,832,081 12 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 500,917 +227 < 0.01% $2,339,281 30 qtrs
STATE STREET CORPORATION Added 466,720 +224,620 < 0.01% $2,179,582 2 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 294,268 +110,468 < 0.01% $1,374,232 15 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 09, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
0
Shared
20,353
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.